• 11.6% growth in Revenue to $140.3m
• 10.7% growth in Underlying EBITDA to $35.6m
• 5.5% growth in Underlying NPAT to $15.8m, in line with guidance

Monash IVF Group reported strong financial results for the first half of fiscal year 2025, with 11.6% growth in revenue to $140.3 million and 10.7% growth in Underlying EBITDA to $35.6 million. Underlying NPAT increased by 5.5% to $15.8 million, in line with guidance provided at the 2024 AGM. The company's diversification across domestic and international operations, as well as its expansion into ultrasound and day surgery services, helped mitigate the impact of short-term industry volatility. In Australia, Monash IVF's stimulated cycles increased by 0.5% compared to the prior corresponding period, while the Australian industry saw a 2.1% decrease. The company's market share in stimulated cycles and frozen embryo transfers grew during the period. Internationally, Monash IVF's stimulated cycles increased by 8.1%, with strong performance in Malaysia and Singapore. The company also successfully exited its underperforming Jakarta minority interest. Monash IVF remains focused on investing in future growth, including the relocation and expansion of its Singapore clinic and the ongoing development of new patient management systems and laboratory equipment.

Monash IVF Group's Underlying NPAT for the full year FY25 is expected to be in line with the guidance provided at the 2024 AGM.

The company believes the long-term fundamentals of the IVF industry remain compelling, with traditional demand drivers such as advanced maternal age and improving pregnancy rates, as well as new demand drivers like genetics and egg freezing, expected to support industry growth of 2-3% over time. Monash IVF's diversification and investment in future growth initiatives position the company well to navigate short-term industry volatility.